NEW YORK (GenomeWeb) – Trovagene today priced a public offering of about 4.4 million shares of its common stock, anticipating gross proceeds of $20 million.

The company will use the proceeds to fund its R&D work and for working capital and other general corporate purposes. The offering is expected to close on or about Feb. 11. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.